CLN5

Across TCGA pan-cancer cohorts, CLN5 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CLN5 data layer compared with 21 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CLN5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CLN5 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, HNSC, and LSCC are the cancer types where CLN5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	1.000	0.625	.004	19	view →
HNSC	DFS	Median	III,IV	0.267	0.895	.003	16	view →
LSCC	DFS	Quartile	III,IV	0.970	0.442	.022	6	view →
PDAC	OS	Median	IV	0.472	0.951	.010	6	view →
CCRCC	DFS	Median	III,IV	0.399	0.932	.022	6	view →
GBM	DFS	Quartile	All	0.235	0.461	.012	5	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CLN5–LUAD (OS)

Open the LUAD breakdown →